GlaxoSmithKline submits regulatory application for UMEC/VI
Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD).
Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD).
UMEC/VI is an investigational once-daily LAMA/LABA combination medicine. It includes properties, umeclidinium bromide --- a long-acting muscarinic antagonist (LAMA)--- and vilanterol, a long-acting beta2 agonist which is administered using the Ellipta inhaler.
The application proposes the proprietary name Anora Ellipta and has been submitted to the US Food and Drug Administration for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.
Applications for UMEC/VI are also planned in the European Union and in other countries next year.
FSTE 100 company GSK is a leading research-based pharmaceutical and healthcare company.
Theravance is a biopharmaceutical company which collaborates with a number of pharmaceutical organisations.
RD